{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(4 Suppl 1)"],"submitter":[null],"journal":["Gastrointestinal cancer research : GCR"],"pagination":["S20-S27"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4812840"],"repository":["biostudies-literature"],"pubmed_title":["Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)"],"pmcid":["PMC4812840"],"additional_accession":[]},"is_claimable":false,"name":"Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)","description":null,"dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Sep","modification":"2025-04-27T01:24:31.854Z","creation":"2025-04-06T18:10:59.655Z"},"accession":"S-EPMC4812840","cross_references":{}}